Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

导出 OA

翻译打印收藏纠错

作者： Kenneth H,Mayer ^[1] ; Kelly E,Seaton ^[2] ; Yunda,Huang ^[3] ; Nicole,Grunenberg ^[3] ; Abby,Isaacs ^[3] ; Mary,Allen ^[4] ; Julie E,Ledgerwood ^[5] ; Ian,Frank ^[6] ; Magdalena E,Sobieszczyk ^[7] ; Lindsey R,Baden ^[8] ; Benigno,Rodriguez ^[9] ; Hong,Van Tieu ^[10] ; Georgia D,Tomaras ^[2] ; Aaron,Deal ^[11] ; Derrick,Goodman ^[2] ; Robert T,Bailer ^[2] ; Guido,Ferrari ^[5] ; Ryan,Jensen ^[2] ; John,Hural ^[11] ; Barney S,Graham ^[3] ; John R,Mascola ^[3] ; Lawrence,Corey ^[5] ; David C,Montefiori ^[5] ; HVTN 104 Protocol Team ^[3] ; and the NIAID HIV Vaccine Trials Network ^[2]

作者单位： Fenway Health, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America. ^[1] Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America. ^[2] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. ^[3] Division of AIDS, NIAID, Bethesda, Maryland, United States of America. ^[4] Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, United States of America. ^[5] Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America. ^[6] College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, United States of America. ^[7] Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America. ^[8] Case Western University, Cleveland, Ohio, United States of America. ^[9] New York Blood Center, New York, New York, United States of America. ^[10] Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America. ^[11]